Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Finished Goods came in at $44.0 million in Q2 2026, up 30.48% YoY from $33.7 million in Q2 2025, and up 12.97% on a QoQ basis from $39.0 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 9 years of Finished Goods data on file, last reported at $44.0 million in Q2 2026.
- Quarterly Finished Goods rose 30.48% year-over-year to $44.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $44.0 million (up 30.48% YoY) and the FY2025 annual result came in at $32.3 million, up 22.34% from the prior year.
- Finished Goods improved to $44.0 million in Q2 2026, from $39.0 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $44.0 million in Q2 2026 to a low of $10.4 million in Q1 2022.
- A 5-year average of $28.0 million and a median of $27.8 million in 2023 frame the typical range for Finished Goods.
- The widest YoY moves for Finished Goods: up 265.54% in 2022, down 24.18% in 2022.
- Tracing ALNY's Finished Goods over 5 years: stood at $25.6 million in 2022, then decreased by 1.89% to $25.1 million in 2023, then climbed by 5.21% to $26.4 million in 2024, then climbed by 22.34% to $32.3 million in 2025, then surged by 36.18% to $44.0 million in 2026.
- The last three Finished Goods figures came in at $44.0 million (Q2 2026), $39.0 million (Q1 2026), and $32.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.04 Mn |
| Mar 31, 2026 | 38.98 Mn |
| Dec 31, 2025 | 32.34 Mn |
| Sep 30, 2025 | 38.85 Mn |
| Jun 30, 2025 | 33.75 Mn |
| Mar 31, 2025 | 32.96 Mn |
| Dec 31, 2024 | 26.43 Mn |
| Sep 30, 2024 | 23.13 Mn |
| Jun 30, 2024 | 27.86 Mn |
| Mar 31, 2024 | 24.82 Mn |
| Dec 31, 2023 | 25.12 Mn |
| Sep 30, 2023 | 27.66 Mn |
| Jun 30, 2023 | 28.51 Mn |
| Mar 31, 2023 | 29.53 Mn |
| Dec 31, 2022 | 25.61 Mn |
| Sep 30, 2022 | 21.48 Mn |
| Jun 30, 2022 | 13.19 Mn |
| Mar 31, 2022 | 10.43 Mn |
| Dec 31, 2021 | 7.01 Mn |
| Sep 30, 2021 | 12.67 Mn |